interleukin-23 – Talk Bio

Next-Generation Psoriasis Drugs Aim to Reshape Treatment Landscape

1 month ago talkbio0Tagged Approved, Clinical Trials, icotrokinra, inhibitors, interleukin-23, next-generation biologics, oral peptides, Piclidenoson, TYK2 gene, United States Food and Drug Administration, Vunakizumab

psoriasis; next-generation biologics; icotrokinra; IL-23 inhibitors; oral peptides; TYK2 inhibitors; vunakizumab; piclidenoson; clinical trials; FDA approval

Innovent’s IL-23 Drug Picankibart Shows Promising Results in Phase 3 Trial for Moderate to Severe Plaque Psoriasis

12 months ago talkbio0Tagged acceptance, Chinese Language, Clinical Trials, Dental Plaque, inhibitors, Innovent, interleukin-23, NDA, Phase 3, Phase 3, picankibart, Regulators (device)

Innovent Biologics, Picankibart, IL-23 inhibitors, Plaque psoriasis, Phase 3 clinical trial, Chinese regulators, NDA acceptance

Lilly and J&J Unveil Promising IL-23 Inhibitor Data for Crohn’s Disease, Setting Stage for FDA Decisions

12 months ago talkbio0Tagged Clinical Trials, Crohn 's disease, Decision, Eli, Eli Lilly, inhibitors, interleukin-23, Tremfya, United States Food and Drug Administration

Crohn’s disease, IL-23 inhibitors, Eli Lilly, Johnson & Johnson, Omvoh, Tremfya, clinical trials, FDA decisions.

AbbVie’s Skyrizi Secures Key FDA Approval for Ulcerative Colitis Treatment

1 year ago talkbio0Tagged AbbVie, Approved, Crohn 's disease, Inflammatory Bowel Diseases, Inhibitor, interleukin-23, Skyrizi, Ulcerative Colitis, United States Food and Drug Administration

Skyrizi, AbbVie, FDA approval, ulcerative colitis, inflammatory bowel disease, IL-23 inhibitor, Crohn’s disease

Innovent to Submit IL-23 Psoriasis Drug to Chinese Regulators Following Phase 3 Success

1 year ago talkbio0Tagged China, CLEAR-1, Clinical Research, Dental Plaque, Innovent, interleukin-23, picankibart, Psoriasis, regulatory

Innovent, IL-23, psoriasis, picankibart, phase 3, China, regulatory submission, plaque psoriasis, CLEAR-1 study